Differences in P-glycoprotein activity in human and rodent blood-brain barrier assessed by mechanistic modelling.
Ontology highlight
ABSTRACT: Variation in the efficacy and safety of central nervous system drugs between humans and rodents can be explained by physiological differences between species. An important factor could be P-glycoprotein (Pgp) activity in the blood-brain barrier (BBB), as BBB expression of this drug efflux transporter is reportedly lower in humans compared to mouse and rat and subject to an age-dependent increase. This might complicate animal to human extrapolation of brain drug disposition and toxicity, especially in children. In this study, the potential species-specific effect of BBB Pgp activity on brain drug exposure was investigated. An age-dependent brain PBPK model was used to predict cerebrospinal fluid and brain mass concentrations of Pgp substrate drugs. For digoxin, verapamil and quinidine, in v
SUBMITTER: Verscheijden LFM
PROVIDER: S-EPMC8380243 | biostudies-literature | 2021 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA